GNRH1 and prostate cancer: PCa is one of the most common malignant tumors in men worldwide and the second leading cause of cancer related deaths in US men.34 Androgen deprivation therapy, achieved either by surgical or chemical castration, is the first line treatment against advanced prostate cancer and is also used to treat high-risk disease in combination with local radiation.30 Androgen blockade can be achieved through the administration of gonadotropin-releasing hormone (GnRH) agonists.30